12:00 AM
 | 
Mar 01, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cinquil reslizumab: Phase II data

Data from a double-blind, North American Phase II trial in 106 patients showed that 3 mg/kg of Ception's IV Cinquil once every 28 days for 4 cycles missed the primary endpoint of significantly improving asthma control as measured by change in ACQ score at week 15 vs. placebo (p=0.054). Cinquil did meet the secondary endpoints of a significant reduction in sputum eosinophil counts...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >